Prognostic Significance of Neutrophil to Lymphocyte Ratio in Patient with NonMuscle Invasive Bladder Cancer Who Underwent Intravesical BCG Treatment
Main Article Content
Keywords
Neutrophil to lymphocyte ratio, non-muscle invasive bladder cancer intravesical BCG
Abstract
Urinary bladder cancer (BC) is the ninth most common cancer in the world and the 13th cause of cancer deaths.
Aim of work: The aim of our study was to assess the role of pretreatment neutrophil-to- lymphocyte ratio (NLR) as a predictor of clinical outcomes in patients with non-muscle invasive bladder cancer (NMIBC) who underwent intravesical Bacillus Calmette-Guérin (BCG) treatment.
Methods: This retrospective study was conducted at Ain-shams university hospital and included 100 patients having NMIBC.
Results: NLR can predict recurrence at further follow up cystoscopy at cutoff 3.3 with sensitivity of 89.7%, specificity of 85.2%, PPV of 79.5%, NPV of 92.9% and AUC was 0.90.
Conclusions: Our data showed that a high value of NLR (add cutoff) evaluated preoperatively might be helpful to predict the BCG response and therefore provide critical information for the clinical management of high-risk NMIBC patients together with the prognostic factors already known.
References
2. Ploeg M, Aben KK, Kiemeney LA. The present and future burden of urinary bladder cancer in the world. World J Urol 2009; 27: 289-293.
3. Bruins HM, Veskimae E, Hernandez V, Imamura M, Neuberger MM, Dahm P, et al. The impact of the extent of lymphadenectomy on oncologic outcomes in patients undergoing radical cystectomy for bladder cancer: a systematic review. Eur Urol 2014; 66: 1065-1077.
4. Sylvester RJ, Rodríguez O, Hernández V, Turturica D, Bauerová L, Bruins HM, et al. European Association of Urology (EAU) prognostic factor risk groups for non–muscleinvasive bladder cancer (NMIBC) incorporating the WHO 2004/2016 and WHO 1973 classification systems for grade: an update from the EAU NMIBC Guidelines Panel. European urology, 2021; 79(4), 480-488.
5. Babjuk M, Bohle A, Burger M, Capoun O, Cohen D, Comperat EM, et al. EAU guidelines on nonmuscle-invasive urothelial carcinoma of the
bladder: update 2016. Eur Urol. 2017; 71:447–61.
6. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008; 454:436–44.
7. Grivennikov SI, Greten FR, Karin M. “Immunity, inflammation, and cancer,” Cell, 2010; 140(6): 883–899.
8. Seah JA, Leibowitz-Amit R, Atenafu EG. “Neutrophil- lymphocyte ratio and pathological response to neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer,” Clinical Genitourinary Cancer, 2015; 13(4): e229–e233.
9. Sung HH, Gyun Jeon H, Jeong BC. “Clinical significance of prognosis using the neutrophillymphocyte ratio and erythrocyte sedimentation rate in patients undergoing rad- ical nephroureterectomy for upper urinary tract urothelial car- cinoma,” BJU International, 2015; 115: 587–594.
10. Kyeong-Hyeon B, Heon H, Jae-Wook C, YunSok H, Seock HC, Jun NL, et al. American Urological Association Education and Research,
Inc, 2019.
11. Galdiero MR, Bonavita E, Barajon I, Garlanda C, Mantovani A, Jaillon S. Tumor associated macrophages and neutrophils in cancer. Immunobiology 2013; 218: 1402–10.
12. Getzler I, Bahouth Z, Nativ O, Rubinstein J, Halachmi S. Preoperative neutrophil to lymphocyte ratio improves recurrence prediction
of non-muscle invasive bladder cancer. BMC Urol, 2018; 18(1):90.
13. Yuk HD, Jeong CW, Kwak C, Kim HH, Ku JH. Elevated neutrophil to lymphocyte ratio predicts poor prognosis in non-muscle invasive bladder
cancer patients: initial intravesical Bacillus Calmette-Guerin treatment after transurethral resection of bladder tumor setting. Frontiers in
Oncology, 2019; 8, 642.
14. Favilla V, Castelli T, Urzì D, Reale G, Privitera S, Salici A, et al. Neutrophil to lymphocyte ratio, a biomarker in non-muscle invasive bladder
cancer: a single-institutional longitudinal study. International braz j urol, 2016; 42: 685-693.
15. Kim J, Chung J, Lee E, Chun S, Park D, Byeon K, Choi S, et al. Prognostic Significance of The Neutrophil-To-Lymphocyte Ratio in Patients With Non-Muscle Invasive Bladder Cancer Treated With Intravesical Bacillus Calmette–Guérin and The Relationship With The CUETO Scoring, 2020. DOI:10.21203/rs.3.rs-116331/v1.
16. Mano R, Baniel J, Shoshany O, Margel D, BarOn T, Nativ O, et al. Neutrophil-to-lymphocyte ratio predicts progression and recurrence of nonmuscle-invasive bladder cancer. Urol Oncol. 2015; 33(2):67.e1–7.
17. Albayrak S, Zengin K, Tanik S, Atar M, Unal SH, Imamoglu MA, et al. Can the neutrophil-tolymphocyte ratio be used to predict recurrence and progression of non-muscle-invasive bladder cancer? Kaohsiung J Med Sci. 2016; 32(6):327–33. Available from:.
https://doi.org/10.1016/j.kjms.2016.05.001.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.